Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 81

1.

Preferred Clinician Communication About Stopping Cancer Screening Among Older US Adults: Results From a National Survey.

Schoenborn NL, Janssen EM, Boyd CM, Bridges JFP, Wolff AC, Pollack CE.

JAMA Oncol. 2018 Jun 28. doi: 10.1001/jamaoncol.2018.2100. [Epub ahead of print] No abstract available.

PMID:
29955796
2.

Proteomics Approach To Trace Site-Specific Damage in Aquatic Extracellular Enzymes During Photoinactivation.

Egli CM, Janssen EM.

Environ Sci Technol. 2018 Jul 17;52(14):7671-7679. doi: 10.1021/acs.est.7b06439. Epub 2018 Jul 5.

PMID:
29920080
3.

Engaging patients and caregivers in prioritizing symptoms impacting quality of life for Duchenne and Becker muscular dystrophy.

Hollin IL, Peay H, Fischer R, Janssen EM, Bridges JFP.

Qual Life Res. 2018 May 26. doi: 10.1007/s11136-018-1891-7. [Epub ahead of print]

PMID:
29804169
4.

Identifying and prioritizing concerns associated with prosthetic devices for use in a benefit-risk assessment: a mixed-methods approach.

Janssen EM, Benz HL, Tsai JH, Bridges JF.

Expert Rev Med Devices. 2018 May;15(5):385-398. doi: 10.1080/17434440.2018.1470505. Epub 2018 May 8.

PMID:
29707973
5.

Project Transform: engaging patient advocates to share their perspectives on improving research, treatment and policy.

Bridges JFP, Janssen EM, Ferris A, Dy SM.

Curr Med Res Opin. 2018 Mar 9:1-8. doi: 10.1080/03007995.2018.1440199. [Epub ahead of print]

PMID:
29429378
6.

Conducting a Discrete-Choice Experiment Study Following Recommendations for Good Research Practices: An Application for Eliciting Patient Preferences for Diabetes Treatments.

Janssen EM, Hauber AB, Bridges JFP.

Value Health. 2018 Jan;21(1):59-68. doi: 10.1016/j.jval.2017.07.001. Epub 2017 Aug 7.

PMID:
29304942
7.

Live, Learn, Pass It on: A Patient Advocacy Engagement Project on the Lived Experience of Lung Cancer Survivors.

Dy SM, Janssen EM, Ferris A, Bridges JF.

J Patient Exp. 2017 Dec;4(4):162-168. doi: 10.1177/2374373517714451. Epub 2017 Jun 16.

8.

STING, DCs and the link between innate and adaptive tumor immunity.

Vatner RE, Janssen EM.

Mol Immunol. 2017 Dec 20. pii: S0161-5890(17)30594-1. doi: 10.1016/j.molimm.2017.12.001. [Epub ahead of print]

9.

Magnitude and Mechanism of Siderophore-Mediated Competition at Low Iron Solubility in the Pseudomonas aeruginosa Pyochelin System.

Schiessl KT, Janssen EM, Kraemer SM, McNeill K, Ackermann M.

Front Microbiol. 2017 Oct 10;8:1964. doi: 10.3389/fmicb.2017.01964. eCollection 2017.

10.

Education and patient preferences for treating type 2 diabetes: a stratified discrete-choice experiment.

Janssen EM, Longo DR, Bardsley JK, Bridges JF.

Patient Prefer Adherence. 2017 Oct 6;11:1729-1736. doi: 10.2147/PPA.S139471. eCollection 2017.

11.

Improving the quality of discrete-choice experiments in health: how can we assess validity and reliability?

Janssen EM, Marshall DA, Hauber AB, Bridges JFP.

Expert Rev Pharmacoecon Outcomes Res. 2017 Dec;17(6):531-542. doi: 10.1080/14737167.2017.1389648. Epub 2017 Oct 23. Review.

PMID:
29058478
12.

Art and Science of Instrument Development for Stated-Preference Methods.

Janssen EM, Bridges JFP.

Patient. 2017 Aug;10(4):377-379. doi: 10.1007/s40271-017-0261-9. No abstract available.

PMID:
28616767
13.

A holistic approach to food safety risks: Food fraud as an example.

Marvin HJP, Bouzembrak Y, Janssen EM, van der Fels-Klerx HJ, van Asselt ED, Kleter GA.

Food Res Int. 2016 Nov;89(Pt 1):463-470. doi: 10.1016/j.foodres.2016.08.028. Epub 2016 Aug 25.

PMID:
28460939
14.

Environmental photochemistry of fenamate NSAIDs and their radical intermediates.

Davis CA, Erickson PR, McNeill K, Janssen EML.

Environ Sci Process Impacts. 2017 May 24;19(5):656-665. doi: 10.1039/c7em00079k.

PMID:
28401228
15.

A cost analysis of implementing a behavioral weight loss intervention in community mental health settings: Results from the ACHIEVE trial.

Janssen EM, Jerome GJ, Dalcin AT, Gennusa JV 3rd, Goldsholl S, Frick KD, Wang NY, Appel LJ, Daumit GL.

Obesity (Silver Spring). 2017 Jun;25(6):1006-1013. doi: 10.1002/oby.21836. Epub 2017 Apr 11.

16.

Type I interferons regulate susceptibility to inflammation-induced preterm birth.

Cappelletti M, Presicce P, Lawson MJ, Chaturvedi V, Stankiewicz TE, Vanoni S, Harley IT, McAlees JW, Giles DA, Moreno-Fernandez ME, Rueda CM, Senthamaraikannan P, Sun X, Karns R, Hoebe K, Janssen EM, Karp CL, Hildeman DA, Hogan SP, Kallapur SG, Chougnet CA, Way SS, Divanovic S.

JCI Insight. 2017 Mar 9;2(5):e91288. doi: 10.1172/jci.insight.91288.

17.

Application of Bayesian networks for hazard ranking of nanomaterials to support human health risk assessment.

Marvin HJ, Bouzembrak Y, Janssen EM, van der Zande M, Murphy F, Sheehan B, Mullins M, Bouwmeester H.

Nanotoxicology. 2017 Feb;11(1):123-133. doi: 10.1080/17435390.2016.1278481.

PMID:
28044458
18.

Caregiver Treatment Preferences for Children with a New Versus Existing Attention-Deficit/Hyperactivity Disorder Diagnosis.

dosReis S, Park A, Ng X, Frosch E, Reeves G, Cunningham C, Janssen EM, Bridges JFP.

J Child Adolesc Psychopharmacol. 2017 Apr;27(3):234-242. doi: 10.1089/cap.2016.0157. Epub 2016 Dec 19.

19.

Big data in food safety: An overview.

Marvin HJ, Janssen EM, Bouzembrak Y, Hendriksen PJ, Staats M.

Crit Rev Food Sci Nutr. 2017 Jul 24;57(11):2286-2295. doi: 10.1080/10408398.2016.1257481. Review.

PMID:
27819478
20.

Using Best-Worst Scaling to Investigate Preferences in Health Care.

Cheung KL, Wijnen BF, Hollin IL, Janssen EM, Bridges JF, Evers SM, Hiligsmann M.

Pharmacoeconomics. 2016 Dec;34(12):1195-1209. Review.

21.

Dendritic Cells as Vaccines: Key Regulators of Tolerance and Immunity.

Tel J, Benitez-Ribas D, Janssen EM, Smits EL, Jacobs JF.

Mediators Inflamm. 2016;2016:5789725. doi: 10.1155/2016/5789725. Epub 2016 May 31. No abstract available.

22.

Dendritic Cells in Systemic Lupus Erythematosus: From Pathogenic Players to Therapeutic Tools.

Klarquist J, Zhou Z, Shen N, Janssen EM.

Mediators Inflamm. 2016;2016:5045248. doi: 10.1155/2016/5045248. Epub 2016 Mar 30. Review.

23.

A Framework for Instrument Development of a Choice Experiment: An Application to Type 2 Diabetes.

Janssen EM, Segal JB, Bridges JF.

Patient. 2016 Oct;9(5):465-79. doi: 10.1007/s40271-016-0170-3.

PMID:
27120338
24.

The bm12 Inducible Model of Systemic Lupus Erythematosus (SLE) in C57BL/6 Mice.

Klarquist J, Janssen EM.

J Vis Exp. 2015 Nov 1;(105):e53319. doi: 10.3791/53319.

25.

Environmental Photochemistry of Amino Acids, Peptides and Proteins.

Lundeen RA, Janssen EM, Chu C, Mcneill K.

Chimia (Aarau). 2014 Nov;68(11):812-7. doi: 10.2533/chimia.2014.812.

PMID:
26508490
26.

Ablation of CD8α(+) dendritic cell mediated cross-presentation does not impact atherosclerosis in hyperlipidemic mice.

Legein B, Janssen EM, Theelen TL, Gijbels MJ, Walraven J, Klarquist JS, Hennies CM, Wouters K, Seijkens TT, Wijnands E, Sluimer JC, Lutgens E, Zenke M, Hildner K, Biessen EA, Temmerman L.

Sci Rep. 2015 Oct 21;5:15414. doi: 10.1038/srep15414.

27.

Loss of Phagocytic and Antigen Cross-Presenting Capacity in Aging Dendritic Cells Is Associated with Mitochondrial Dysfunction.

Chougnet CA, Thacker RI, Shehata HM, Hennies CM, Lehn MA, Lages CS, Janssen EM.

J Immunol. 2015 Sep 15;195(6):2624-32. doi: 10.4049/jimmunol.1501006. Epub 2015 Aug 5.

28.

Quantitating MHC class II trafficking in primary dendritic cells using imaging flow cytometry.

Hennies CM, Lehn MA, Janssen EM.

J Immunol Methods. 2015 Aug;423:18-28. doi: 10.1016/j.jim.2015.04.023. Epub 2015 May 9.

29.

Review of the evidence: prevalence of medical conditions in the United States population with serious mental illness.

Janssen EM, McGinty EE, Azrin ST, Juliano-Bult D, Daumit GL.

Gen Hosp Psychiatry. 2015 May-Jun;37(3):199-222. doi: 10.1016/j.genhosppsych.2015.03.004. Epub 2015 Mar 14. Review.

30.

Aquatic photochemical kinetics of benzotriazole and structurally related compounds.

Janssen EM, Marron E, McNeill K.

Environ Sci Process Impacts. 2015 May;17(5):939-46. doi: 10.1039/c5em00045a. Epub 2015 Mar 27.

PMID:
25816109
31.

Environmental photoinactivation of extracellular phosphatases and the effects of dissolved organic matter.

Janssen EM, McNeill K.

Environ Sci Technol. 2015 Jan 20;49(2):889-96.

PMID:
25495644
32.

STING-mediated DNA sensing promotes antitumor and autoimmune responses to dying cells.

Klarquist J, Hennies CM, Lehn MA, Reboulet RA, Feau S, Janssen EM.

J Immunol. 2014 Dec 15;193(12):6124-34. doi: 10.4049/jimmunol.1401869. Epub 2014 Nov 10.

33.

DNA methylation dynamics during ex vivo differentiation and maturation of human dendritic cells.

Zhang X, Ulm A, Somineni HK, Oh S, Weirauch MT, Zhang HX, Chen X, Lehn MA, Janssen EM, Ji H.

Epigenetics Chromatin. 2014 Aug 20;7:21. doi: 10.1186/1756-8935-7-21. eCollection 2014.

34.

Dual roles of dissolved organic matter as sensitizer and quencher in the photooxidation of tryptophan.

Janssen EM, Erickson PR, McNeill K.

Environ Sci Technol. 2014 May 6;48(9):4916-24. doi: 10.1021/es500535a. Epub 2014 Apr 21.

PMID:
24708197
35.

Respond to "No antigen-presentation defect in Unc93b1(3d/3d) (3d) mice".

Tabeta K, Hoebe K, Janssen EM, Xia Y, Beutler B.

Nat Immunol. 2013 Nov;14(11):1102-3. doi: 10.1038/ni.2734. No abstract available.

PMID:
24145779
36.

Biological responses to activated carbon amendments in sediment remediation.

Janssen EM, Beckingham BA.

Environ Sci Technol. 2013 Jul 16;47(14):7595-607. doi: 10.1021/es401142e. Epub 2013 Jun 28.

PMID:
23745511
37.

Evaluation of different substrates for inkjet printing of rasagiline mesylate.

Genina N, Janßen EM, Breitenbach A, Breitkreutz J, Sandler N.

Eur J Pharm Biopharm. 2013 Nov;85(3 Pt B):1075-83. doi: 10.1016/j.ejpb.2013.03.017. Epub 2013 Apr 4.

PMID:
23563101
38.

Drug-printing by flexographic printing technology--a new manufacturing process for orodispersible films.

Janssen EM, Schliephacke R, Breitenbach A, Breitkreutz J.

Int J Pharm. 2013 Jan 30;441(1-2):818-25. doi: 10.1016/j.ijpharm.2012.12.023. Epub 2012 Dec 21.

PMID:
23266759
39.

Melanoma-infiltrating dendritic cells: Limitations and opportunities of mouse models.

Klarquist JS, Janssen EM.

Oncoimmunology. 2012 Dec 1;1(9):1584-1593.

40.

Cross-presentation of cell-associated antigens by mouse splenic dendritic cell populations.

Thacker RI, Janssen EM.

Front Immunol. 2012 Mar 14;3:41. doi: 10.3389/fimmu.2012.00041. eCollection 2012.

41.

Assessment of nontoxic, secondary effects of sorbent amendment to sediments on the deposit-feeding organism Neanthes arenaceodentata.

Janssen EM, Choi Y, Luthy RG.

Environ Sci Technol. 2012 Apr 3;46(7):4134-41. doi: 10.1021/es204066g. Epub 2012 Mar 14.

PMID:
22372688
42.

Nab2 regulates secondary CD8+ T-cell responses through control of TRAIL expression.

Wolkers MC, Gerlach C, Arens R, Janssen EM, Fitzgerald P, Schumacher TN, Medema JP, Green DR, Schoenberger SP.

Blood. 2012 Jan 19;119(3):798-804. doi: 10.1182/blood-2011-08-373910. Epub 2011 Nov 29.

43.

Immune adjuvant efficacy of CpG oligonucleotide in cancer treatment is founded specifically upon TLR9 function in plasmacytoid dendritic cells.

Nierkens S, den Brok MH, Garcia Z, Togher S, Wagenaars J, Wassink M, Boon L, Ruers TJ, Figdor CG, Schoenberger SP, Adema GJ, Janssen EM.

Cancer Res. 2011 Oct 15;71(20):6428-37. doi: 10.1158/0008-5472.CAN-11-2154. Epub 2011 Jul 25.

44.

Breaking T cell tolerance to beta cell antigens by merocytic dendritic cells.

Katz JD, Janssen EM.

Cell Mol Life Sci. 2011 Sep;68(17):2873-83. doi: 10.1007/s00018-011-0730-6. Epub 2011 May 31. Review.

45.

Interleukin-2 rescues helpless effector CD8+ T cells by diminishing the susceptibility to TRAIL mediated death.

Wolkers MC, Bensinger SJ, Green DR, Schoenberger SP, Janssen EM.

Immunol Lett. 2011 Sep 30;139(1-2):25-32. doi: 10.1016/j.imlet.2011.04.011. Epub 2011 May 20.

46.

PCB-induced changes of a benthic community and expected ecosystem recovery following in situ sorbent amendment.

Janssen EM, Thompson JK, Luoma SN, Luthy RG.

Environ Toxicol Chem. 2011 Aug;30(8):1819-26. doi: 10.1002/etc.574. Epub 2011 Jun 14.

PMID:
21560148
47.

In situ measurement of PCB pore water concentration profiles in activated carbon-amended sediment using passive samplers.

Oen AM, Janssen EM, Cornelissen G, Breedveld GD, Eek E, Luthy RG.

Environ Sci Technol. 2011 May 1;45(9):4053-9. doi: 10.1021/es200174v. Epub 2011 Apr 7.

PMID:
21473574
48.

Selective expansion of merocytic dendritic cells and CD8DCs confers anti-tumour effect of Fms-like tyrosine kinase 3-ligand treatment in vivo.

Hennies CM, Reboulet RA, Garcia Z, Nierkens S, Wolkers MC, Janssen EM.

Clin Exp Immunol. 2011 Mar;163(3):381-91. doi: 10.1111/j.1365-2249.2010.04305.x. Epub 2011 Jan 14.

49.

Harnessing dendritic cells for tumor antigen presentation.

Nierkens S, Janssen EM.

Cancers (Basel). 2011 Apr 26;3(2):2195-213. doi: 10.3390/cancers3022195.

50.

Assessment of field-related influences on polychlorinated biphenyl exposures and sorbent amendment using polychaete bioassays and passive sampler measurements.

Janssen EM, Oen AM, Luoma SN, Luthy RG.

Environ Toxicol Chem. 2011 Jan;30(1):173-80. doi: 10.1002/etc.367.

PMID:
20872900

Supplemental Content

Loading ...
Support Center